BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, September 9, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Aurigene Oncology reports potent and selective degraders of SMARCA2 and SMARCA4 as cancer therapeutics
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Aurigene Oncology reports potent and selective degraders of SMARCA2 and SMARCA4 as cancer therapeutics
Oct. 16, 2023
No Comments
At the AACR-NCI-EORTC meeting in Boston, Aurigene Oncology Ltd. reported their research on paralogue selective degraders of SMARCA2 (AU-SM2-1) and SMARCA4 (AU-SM4-1).
BioWorld Science
Conferences
Cancer